RS107404A - Method of treating ischemia perefusion injury using adenosine receptor antagonists - Google Patents

Method of treating ischemia perefusion injury using adenosine receptor antagonists

Info

Publication number
RS107404A
RS107404A YUP-1074/04A YUP107404A RS107404A RS 107404 A RS107404 A RS 107404A YU P107404 A YUP107404 A YU P107404A RS 107404 A RS107404 A RS 107404A
Authority
RS
Serbia
Prior art keywords
receptor antagonists
injury
adenosine receptor
perefusion
treating ischemia
Prior art date
Application number
YUP-1074/04A
Other languages
English (en)
Inventor
Glenn Smits
Xiaowei Jin
Garrett Gross
John Auchampach
Original Assignee
Biogen Idec Ma Inc.,
The Mcw Research Foundation Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc.,, The Mcw Research Foundation Inc., filed Critical Biogen Idec Ma Inc.,
Publication of RS107404A publication Critical patent/RS107404A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Opisani su postupci korisni za sprečavanje, ograničavanje ili lečenje ishemične reperfuzione povrede kod sisara. Konkretnije, ovaj pronalazak se odnosi na davanje antagonista adenozinskog receptora A2b u cilju sprečavanja, ograničavanja ili lečenja ishemične reperfuzione povrede.
YUP-1074/04A 2002-06-12 2003-06-12 Method of treating ischemia perefusion injury using adenosine receptor antagonists RS107404A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38868002P 2002-06-12 2002-06-12
PCT/US2003/018695 WO2003105666A2 (en) 2002-06-12 2003-06-12 Method of treating ischemia reperfusion injury using adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
RS107404A true RS107404A (en) 2007-02-05

Family

ID=29736516

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-1074/04A RS107404A (en) 2002-06-12 2003-06-12 Method of treating ischemia perefusion injury using adenosine receptor antagonists

Country Status (18)

Country Link
US (1) US20050203065A1 (sr)
EP (1) EP1513848A4 (sr)
JP (1) JP2005533054A (sr)
CN (1) CN1671716A (sr)
AU (1) AU2003236509A1 (sr)
BR (1) BR0312137A (sr)
CA (1) CA2489179A1 (sr)
EA (1) EA200500005A1 (sr)
IS (1) IS7592A (sr)
MX (1) MXPA04012629A (sr)
NO (1) NO20050149L (sr)
NZ (1) NZ537444A (sr)
PL (1) PL374498A1 (sr)
RS (1) RS107404A (sr)
SG (1) SG131115A1 (sr)
UA (1) UA84404C2 (sr)
WO (1) WO2003105666A2 (sr)
ZA (1) ZA200500254B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336650B2 (en) 2001-10-25 2008-06-05 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
JP2008534453A (ja) * 2005-03-24 2008-08-28 バイエル・ヘルスケア・アクチェンゲゼルシャフト 再灌流傷害および再灌流障害の処置のための置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジンの使用
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
TWI404537B (zh) * 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012141255A1 (ja) * 2011-04-12 2012-10-18 株式会社 資生堂 美白剤およびメラニン生成抑制剤
CN102274232B (zh) * 2011-06-22 2013-03-27 南京理工大学 腺苷受体a1拮抗剂在制备药物中的应用
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN105209447B (zh) * 2013-03-14 2017-11-21 百时美施贵宝公司 双环[2.2.2]酸gpr120调节剂
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
JP2003513976A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストおよびこれを作製し使用する方法
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease

Also Published As

Publication number Publication date
IS7592A (is) 2004-12-10
WO2003105666A3 (en) 2004-09-16
PL374498A1 (en) 2005-10-31
BR0312137A (pt) 2005-04-05
NO20050149D0 (no) 2005-01-11
AU2003236509A1 (en) 2003-12-31
UA84404C2 (ru) 2008-10-27
MXPA04012629A (es) 2005-10-18
JP2005533054A (ja) 2005-11-04
ZA200500254B (en) 2006-04-26
CA2489179A1 (en) 2003-12-24
NZ537444A (en) 2006-09-29
NO20050149L (no) 2005-03-11
SG131115A1 (en) 2007-04-26
CN1671716A (zh) 2005-09-21
EP1513848A2 (en) 2005-03-16
WO2003105666A2 (en) 2003-12-24
US20050203065A1 (en) 2005-09-15
EA200500005A1 (ru) 2005-06-30
EP1513848A4 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
WO2003105666A3 (en) METHOD OF TREATING LESIONS CONSEQUENCES TO ISCHEMIC PERFUSION USING ADENOSINE RECEPTOR ANTAGONISTS
WO2004058148A3 (en) Mitotic kinesin inhibitors
IL165624A0 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
EP1492487A4 (en) INHIBITORS OF MITOTIC KINESIN
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESIN
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
EP1551812A4 (en) MITOTIC KINESINE HEMMER
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESIN
EP1481077A4 (en) MITOTIC KINESINE HEMMER
MXPA04003103A (es) Derivados de bencimidazolidinona como agentes muscarinicos.
TW200633980A (en) Pyridones useful as inhibitors of kinases
EP1628623A4 (en) METHOD FOR THE TREATMENT OF DISEASES WITH HSP90-INHIBITING AGENTS COMBINED WITH ENZYME-INHIBITORS
PL1608400T3 (pl) Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73
MY129445A (en) Compositions for treating inflammatory response
WO2006130433A3 (en) Treatment of ischemia using stem cells
WO2006031348A3 (en) Mitotic kinesin inhibitors
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2006023440A3 (en) Mitotic kinesin inhibitors
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
EP1635641A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2004087050A3 (en) Mitotic kinesin inhibitors
WO2004043353A3 (en) Compositions and methods for treating acute myeloid leukemia